Ankasa Regenerative Therapeutics
La Jolla, US · Founded 2014 · Delaware corporation · 2 known investors
Ankasa Regenerative Therapeutics develops ART352-L, a protein-based stem cell activation therapy using human Wnt proteins to enhance bone formation and tissue regeneration in reconstructive surgeries. Its lead indication is augmenting autograft in spinal fusion for degenerative disc conditions, with potential expansion to dental/orthopedic implant osseointegration, fracture repair, and joint arthroplasty.
BiotechLongevityMedical Devices
Founders & leadership
DD
Douglas DownsExecutive
SJ
Sanford J. MadiganExecutive
Board
KK
Kevin KinsellaBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$15.5M disclosed across 2 rounds · 2015–2020
▶$6MraisedOct 2020 · 4 investors · BiotechnologyRule 506(b)
▶$6MraisedOct 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sanford J. MadiganExecutive Officer, Director
- Kevin KinsellaDirector
- Andre Kobelt, Ph.D.Director
- Tighe ReardonExecutive Officer
- Offering amount
- $12M
- Amount sold
- $6M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MraisedAug 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$9.5MraisedAug 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas DownsExecutive Officer, Director
- Kevin KinsellaDirector
- Sanford J. MadiganExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $9.5M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ankasa Regenerative Therapeutics do?
- Ankasa Regenerative Therapeutics develops ART352-L, a protein-based stem cell activation therapy using human Wnt proteins to enhance bone formation and tissue regeneration in reconstructive surgeries. Its lead indication is augmenting autograft in spinal fusion for degenerative disc conditions, with potential expansion to dental/orthopedic implant osseointegration, fracture repair, and joint arthroplasty.
- Who are Ankasa Regenerative Therapeutics's investors?
- Ankasa Regenerative Therapeutics's investors include Correlation Ventures, Stanford University.
- How much funding has Ankasa Regenerative Therapeutics raised?
- Ankasa Regenerative Therapeutics has disclosed $15.5M raised across 2 rounds.
- Where is Ankasa Regenerative Therapeutics headquartered?
- Ankasa Regenerative Therapeutics is headquartered in La Jolla, US.